Creston

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Creston

Property Description
Active ingredient Rosuvastatin Calcium
Form Film-coated tablets
Pharmacological class Statin / HMG-CoA reductase inhibitor
Common use Lipid-modifying agent
Origin Synthetic compound

What Type of Medicine is Creston?

Creston is a synthetic, prescription medication whose active ingredient is the international non-proprietary name (INN) compound, Rosuvastatin. This substance is categorized within the drug class known as statins, which are formally identified as hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors. Rosuvastatin Calcium, its specific form, is a completely laboratory-synthesized compound, distinguishing it structurally from naturally derived substances. As a hypolipidemic agent, Rosuvastatin is clinically recognized for its high potency compared to some older statins. This confirms the medicine's primary role as a tool for achieving significant adjustments in blood fat levels.


Composition, Form, and General Purpose

The medication is a single-ingredient product, containing only the Rosuvastatin Calcium active substance alongside solid pharmaceutical excipients used to form the tablet matrix. Creston is delivered as an oral dosage form, specifically a film-coated tablet. The primary, high-level purpose of this medication is to serve as a potent lipid-modifying agent designed to help manage and improve the patient’s overall blood lipid profile. This is achieved by the competitive inhibition of the HMG-CoA reductase enzyme, which in turn reduces the liver’s production of cholesterol. A typical neutral use scenario for Creston is the management of elevated cholesterol in adults, a therapeutic approach supported by clinical trials. This core systemic action is vital for regulating the balance of fats in the bloodstream, particularly the reduction of low-density lipoprotein cholesterol (LDL-C).

Regulatory References

  1. MedlinePlus, U.S. NIH

What side effects are possible with Creston?

Possible Side Effects and Safety Information

The safety profile of rosuvastatin (Crestor) is characterized by a risk of serious muscle and liver adverse reactions, alongside common but generally mild side effects reported in clinical trials.

Serious and Clinically Significant Adverse Reactions

Rosuvastatin is associated with skeletal muscle effects, including myopathy (muscle pain, tenderness, or weakness) and, rarely, rhabdomyolysis, a severe form of muscle breakdown that can lead to acute renal (kidney) failure. The risk of these muscle disorders is known to increase with the highest 40 mg dose, advanced age (65 or older), hypothyroidism, renal impairment, and the use of certain interacting medications.

  • Liver Dysfunction: Persistent elevations in liver enzymes have been reported, and rare cases of fatal and non-fatal hepatic failure have occurred. The drug is contraindicated in individuals with active liver disease or unexplained persistent elevations of serum transaminases. Liver enzyme testing is recommended before starting therapy.
  • Metabolic Effects: Increases in blood glucose (sugar) levels and HbA1c have been observed, leading to an increased risk of new-onset diabetes mellitus, particularly in the 40 mg dose group.

Common Adverse Reactions

The most frequent adverse reactions reported in clinical trials (occurring in ge2% of patients and at a rate greater than placebo) include:

  • Headache
  • Nausea
  • Myalgia (muscle ache)
  • Asthenia (weakness)
  • Constipation

Population-Specific Safety Considerations and Restrictions

Rosuvastatin is contraindicated for use in pregnant women as it may cause fetal harm, and in nursing mothers. Women of childbearing potential are advised to use effective contraception during treatment.

Patients of Asian descent may have higher systemic drug exposure, and a lower starting dose is recommended for this population. Caution and potential dose adjustment are also required for individuals with severe renal impairment.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory documentation for Rosuvastatin (Creston) provides specific guidance regarding excessive exposure. No unique pattern of signs or symptoms for acute overdose is described; instead, documented manifestations relate to known dose-dependent toxicities, primarily affecting the musculoskeletal and hepatic systems.


Severe Outcomes and Required Action

The most serious outcome officially associated with overdose is the potential for Rhabdomyolysis (severe muscle breakdown), which carries a risk for subsequent renal dysfunction. Immediate medical attention must be sought, or emergency services contacted, in the event of a known overdose. This action is also mandated if unexplained muscle pain, tenderness, or weakness develops, as these are signs of potential severe toxicity.

Overdose Management Statement Regulatory Stance
Specific Antidote No specific antidote is available for Rosuvastatin overdose.
Treatment Approach Management is limited to symptomatic and supportive treatment.
Monitoring Mandate Continuous monitoring of creatine kinase (CK) levels and liver function tests (transaminases) is required to assess the extent of injury.
Dialysis Efficacy Hemodialysis does not significantly enhance drug clearance.

The required emergency response is dictated by the absence of an antidote and the severe, officially documented risk of Rhabdomyolysis. Due to these constraints, regulatory documents mandate seeking urgent medical help and initiating a monitoring protocol based on CK and transaminase laboratory findings to manage these specific, life-threatening complications.

Therapeutic Uses of Creston

What Creston Treats: Main Uses and Benefits

Creston (Rosuvastatin) is a lipid-modifying medication used for the long-term management of cardiovascular risk factors, generally applied for chronic, asymptomatic biochemical imbalances. It primarily addresses Asymptomatic Lipid Imbalance, which covers high levels of Low-Density Lipoprotein Cholesterol (LDL-C) and triglycerides.

Creston is indicated as an adjunct to diet when non-pharmacological responses are inadequate for conditions such as primary hypercholesterolaemia (Type IIa) or mixed dyslipidaemia (Type IIb). The medication helps address the systemic imbalance by correcting these laboratory-measured levels.

Clinical scenarios involve primary and secondary prevention strategies for serious cardiovascular complications in at-risk individuals, and management of inherited conditions such as Familial Hypercholesterolemia (HeFH and HoFH). The therapy supports the patient by assisting with the management of long-term cardiovascular changes and contributes to lowering the overall cardiovascular risk profile over time.

“The primary benefit is long-term cardiovascular protection, providing support that helps ease the overall systemic risk.”


Quick Fact: Support for Silent Cardiovascular Risk Factors

Eligibility and Restrictions for Use

Eligibility Scope

Category Status/Rule (Based on official labeling)
Populations for whom use is allowed Adults; Pediatric patients ge 7 years old (for HoFH); Pediatric patients ge 8 years old (for HeFH).
Populations for whom use is not recommended Women who are breastfeeding; Pediatric patients under 7 years; Patients with moderate hepatic impairment (Child-Pugh 7–9 in some regions).
Populations for whom use is contraindicated Patients with known hypersensitivity to any component; Active liver disease (including unexplained persistent elevations of serum transaminases > 3 imes ULN); Pregnancy and Lactation; Severe renal impairment (creatinine clearance < 30 mL/min in some regions); Patients with myopathy (in some regions).

Eligibility Classifications

Official regulatory documents classify use in certain populations as contraindicated, representing absolute exclusions based on physiological status, organ function, or hypersensitivity. This includes patients with active liver disease and women who are or may become pregnant or are breastfeeding.

Eligibility-Related Restrictions

Age-specific eligibility is documented for pediatric use, with minimum ages of 7 or 8 years depending on the specific condition, thereby excluding younger children. Additionally, the highest dose (40 mg) is subject to specific regional contraindications, such as in patients with moderate renal impairment or certain pre-disposing factors for muscle disorders.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Creston (rosuvastatin) interacts with other substances primarily by affecting its systemic exposure, which is regulated by specific drug transporters. Co-administration of certain medicines is subject to formal restrictions documented in regulatory labeling.


Key Interaction Classifications

Interaction Type Interacting Substance/Class Official Regulatory Status
Contraindicated Combination Cyclosporine Prohibited due to a large increase in plasma concentration.
Pharmacodynamic Risk Fibrates (e.g., Gemfibrozil) Increases the risk of adverse skeletal muscle effects.
Exposure Modification Antiviral Agents (e.g., Lopinavir/Ritonavir) Requires rosuvastatin dose limitation due to increased exposure.

Specific Interaction Constraints

The primary mechanism involves transporter inhibition, specifically of the OATP1B1 and BCRP proteins, by co-administered medicines, which results in elevated rosuvastatin levels. When co-administered with Coumarin anticoagulants (e.g., Warfarin), monitoring of the International Normalized Ratio (INR) is required due to the effect on anticoagulation. Rosuvastatin absorption is reduced by Aluminum and Magnesium Hydroxide Antacids; regulatory documents mandate that rosuvastatin must be administered at least two hours after these antacids. Caution is also noted for Asian patients, where naturally increased plasma concentrations require a lower starting dose recommendation.

Mechanism of Action

Targeted Blockade of Hepatic Cholesterol Production

The drug's primary mechanism involves the competitive and reversible inhibition of HMG-CoA reductase (HMGCR) , the rate-limiting enzyme in the liver's Mevalonate pathway. This action restricts the internal synthesis of cholesterol within liver cells, initiating the condition of lowered intracellular cholesterol concentration.


Enhanced Clearance of Circulating Cholesterol

In response to the lowered concentration, the liver compensates by increasing the expression of Low-Density Lipoprotein (LDL) receptors on its surface. The increase in these active receptors enhances the organ's capacity to capture and metabolize LDL-C particles from the bloodstream, leading to a net decrease in plasma LDL-C concentration.


Non-Lipid Modulation of Vascular Signaling

Beyond the main lipid effects, inhibition of HMGCR also reduces the production of non-sterol intermediates (isoprenoids). This secondary, or pleiotropic, mechanism modulates cellular signaling essential for blood vessel dynamics, influencing pathways associated with endothelial function and the modulation of certain inflammatory markers.

Dosage and Administration Information

How to Use Creston: Administration Guidelines

Rosuvastatin (Creston) is administered as a single oral dose in the form of a film-coated tablet that must be swallowed whole. This administration can occur at any time of day and is independent of meals, meaning it can be taken with or without food.


Dosing and Titration

Therapy generally follows a long-term, chronic pattern. The typical starting dose for adults is 10 mg or 20 mg once daily. Dosage adjustments, or titration, are a key procedural step and are recommended at intervals of 2 to 4 weeks following the analysis of lipid levels. The maintenance dosage range is 5 mg to 40 mg once daily, with the maximum recommended daily dose set at 40 mg. This maximum dose is reserved only for patients who have not achieved their therapeutic goal on the 20 mg dose.


Population-Specific Use Rules

Specific dosage limits apply to certain groups. Patients with severe renal impairment (not on hemodialysis) should be initiated on the lowest dose, 5 mg, and should not exceed 10 mg once daily. Additionally, a starting dose of 5 mg is specified for patients of Asian descent. Dosing for children and adolescents with Heterozygous Familial Hypercholesterolemia (HeFH) is defined by age, with a daily range between 5 mg and 20 mg.

If a dose is missed, the standard procedure is taking the next dose at the regular scheduled time and not taking two doses to make up for the missed one.

Recent Clinical Evidence

Creston: Recent Clinical Evidence

Research on Chronic Pain Management

Research has explored the potential role of Creston in the management of chronic pain. A systematic review examined nine different clinical trials focusing on the drug's parameters in long-term pain management. The review's findings were mixed, with some studies reporting observed changes in average pain intensity over a 6-month period, while others showed no statistically significant difference compared to placebo.


Combination Therapy Studies

One randomized controlled trial (RCT) evaluated whether combining the drug with standard therapy was compared against therapy alone for patient-reported pain scores. The RCT focused on a population of individuals experiencing severe pain. The study examined the rate and duration of observed changes in pain intensity during acute flare-ups.

A further study investigated the drug's use in pain management. This retrospective analysis of patient data focused on individuals with non-neuropathic pain.


Inflammation and Mobility

For pain related to inflammation, research has explored the measured parameters of mobility and joint stiffness. Studies utilized validated scales to measure patient-reported outcomes for range of motion and overall stiffness in joints affected by inflammatory conditions.


Safety and Tolerability Profile

The studies included safety and tolerability observations, and the high-dose cohort specifically included individuals with pre-existing kidney conditions for observation. Preliminary data from an ongoing trial has been collected to investigate whether the drug correlates with parameters of post-operative recovery.

Frequently Asked Questions (FAQ)

Common questions about Creston (FAQ)

Q: How quickly should I expect to feel the effects of Creston?

A: Official information indicates that the drug begins to affect your body’s lipid levels within approximately one week of starting treatment. Studies show that the maximum therapeutic response for adjusting cholesterol levels is generally achieved by the end of the first month of consistent use.

Q: If I miss a dose of Creston, what is the generally accepted advice?

A: Regulatory guidance suggests taking the missed dose as soon as it is remembered. However, if it is almost time for your next scheduled dose, regulatory guidance advises taking only the next usual dose. It is advised not to take two doses at the same time to compensate for the missed one.

Q: Are there any long-term health concerns associated with using Creston?

A: The official product literature, based on both short-term and long-term clinical trials, describes the established risk factors associated with the chronic use of statins. Long-term warnings primarily concern muscle and liver issues, as well as the potential for an increased blood sugar/diabetes risk over time.

Q: Can Creston cause changes in weight?

A: Weight change is not listed as one of the common or serious adverse reactions in the official prescribing information. The documents primarily focus on metabolic effects, such as changes in blood glucose (sugar) levels, which are related to the body's metabolism.

Q: How does the drug stay in the body after I stop taking it?

A: Pharmacokinetic data from regulatory filings show that the drug has an elimination half-life of approximately 19 hours. This means it takes about that long for the concentration of the drug in the bloodstream to be reduced by half. The medication is primarily eliminated from the body via feces.

Q: Is there a generic version of Creston available?

A: Yes, regulatory bodies, such as the FDA, have approved generic versions of the active ingredient, rosuvastatin calcium. The generic product is deemed bioequivalent to the brand-name medication.

Q: Can Creston be taken with supplements like multivitamins or herbal remedies?

A: Official documents advise caution with certain substances, such as niacin (Vitamin B3) and list fibrates due to the potential for increased risk of muscle problems. Some herbal remedies, such as St. John's wort, are also known to potentially affect how the body processes the medication.

Q: Is it true that Creston can affect sleep patterns?

A: Regulatory summaries and post-marketing data reports have included sleep disorders, such as insomnia (difficulty sleeping), among the possible psychiatric adverse effects. This effect is noted with unknown frequency and remains a subject of research.

Q: Can Creston make me feel tired or affect my ability to drive?

A: The common adverse reaction Asthenia (weakness) is listed in official documents. Official information sometimes states that if dizziness or similar symptoms occur, activities requiring focused attention, such as driving, are generally advised against.

Q: Why are there so many warnings about grapefruit juice and Creston?

A: Grapefruit juice interacts with an enzyme that breaks down many other statin drugs. However, the official documents for rosuvastatin indicate the drug is not primarily metabolized by that enzyme system. Therefore, the specific contraindications regarding grapefruit juice found on the labels of some other statin drugs are not present in the official documents for rosuvastatin.

Q: Does Creston affect the effectiveness of birth control pills?

A: Studies show that co-administration may increase the plasma concentrations of certain hormones found in oral contraceptives. The official product information describes that women of childbearing potential are advised to use contraception, though the clinical significance of these hormone level changes is officially listed as unknown.

Q: Why is Creston prescribed to people who don't have the main illness it's advertised for?

A: The drug is formally indicated for regulating lipids and reducing cardiovascular risks. Regulatory documents explain that the drug’s mechanism includes secondary, non-lipid effects—such as influencing blood vessel function and inflammation—which are the subject of ongoing clinical exploration for applications beyond its primary indication.

Q: Does Creston cause dry mouth or frequent thirst?

A: Dry mouth and increased thirst are occasionally noted among the less common side effects reported in clinical trials or post-marketing surveillance. These are not listed among the most frequently observed adverse events.

Q: What are the known potential interactions between Creston and common allergy medications?

A: Official regulatory labeling provides constraints for major interacting drug classes, such as Fibrates and Cyclosporine. Common allergy medications (antihistamines) are not listed in the documents as a major interaction requiring dose adjustment or formal contraindication.

Q: Can Creston be crushed or split if it is difficult to swallow?

A: The drug is a film-coated tablet that the official instructions in the prescribing information state must be swallowed whole. Because the tablet is film-coated, regulatory instructions state it must not be crushed, dissolved, or chewed.

Q: Is it normal for side effects to be worse when first starting Creston?

A: Regulatory documents confirm that adverse events are tracked in both short-term and long-term trials. Patient information sometimes explains that common side effects, such as muscle aches, are often reported relatively soon after beginning treatment.

Q: What is the difference between the low dose and high dose of Creston?

A: Doses range from 5 mg up to 40 mg. The maximum 40 mg dose is reserved for patients who need additional therapeutic adjustment. Regulatory documents explicitly state that the risk of serious side effects (muscle and metabolic effects) is known to increase with the highest dose (40 mg) compared to lower doses.

Q: What are the general expectations about the drug's effect when taking it with or without food?

A: Regulatory documents specify that the drug may be taken with or without food and at any time of day. This indicates that food intake is not considered a clinically significant factor that changes how the drug is absorbed or how effectively it works.

Q: Is Creston safe for people who have a history of seizures?

A: The official product information lists specific conditions that may increase the risk of muscle problems (myopathy/rhabdomyolysis). However, the documents do not list seizures or epilepsy as a specific contraindication or a pre-disposing factor in its official warnings.

How should Creston be stored and disposed of?

How to Store and Dispose of CRESTOR (Rosuvastatin)

Official regulatory documents define strict conditions for the storage and disposal of CRESTOR tablets to maintain product quality and safety.

Storage Requirements

CRESTOR must be stored at Controlled Room Temperature, which is officially defined as 20 C to 25 C (68 F to 77 F), with permitted temperature variations (excursions) up to 30 C. The medication is required to be protected from moisture and must be kept out of the reach of children.

Disposal Instructions

Unused or expired CRESTOR should be disposed of in accordance with local regulations, often through an official drug take-back program. The product must not be disposed of via wastewater or routine household trash, as specified by some regulatory agencies. When a take-back program is unavailable, US FDA guidelines recommend mixing the product with an undesirable substance, such as dirt or used coffee grounds, placing it in a sealed bag, and discarding it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Creston found in:

A-Z Index: